Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Recruiting · NCT03495024 · Interventional (participants receive a specific treatment) · Lead sponsor: Corporal Michael J. Crescenz VA Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using standardized rating scales. The aim is to examine clinically significant effects on antipsychotic-induced neurological side effects that may warrant further investigation.
Who can take part
Inclusion criteria
- DSM 5 criteria for schizophrenia or schizoaffective disorder and stable disease
- Glazer-Morgenstern-Doucette criteria for TD
- Smoking at least 5 cigarettes on average daily for at least 30 days prior to screening
- An exhaled carbon monoxide concentration greater than 5 parts per million (ppm) at screening
- Agree to stop smoking by the target date (four weeks after baseline
- Concurrence for varenicline treatment from the patient's mental health provider if the patient is under mental health care; OR, if the patient is not under mental health care, the prescribing clinician should consult with a mental health provider to evaluate the patient for appropriateness to receive varenicline
Exclusion criteria
- Have untreated or unstable acute medical or psychiatric illnesses
- Have a history of seizures
- History of somnambulism
- Have chronic degenerative neurological illnesses (e.g., Parkinson's disease)
- Have a history of active substance abuse (including marijuana abuse) in the 3 months prior to screening or a positive toxicology screen
- Are receiving clozapine or cholinesterase inhibitors
- Had a change in dosing or medication type of antipsychotic or anti-muscarinic for one month prior to enrollment (two months for long-acting antipsychotics)
- Are unable to remain on a stable dose of antipsychotic or anti-muscarinic during the study period
- Have acute suicidal ideation, intent or behavior within 12 months or risk based assessed on the C-SSRS or depression/anxiety score ≥ 8 on the HADS.
- Female subjects of childbearing age will have a negative pregnancy serum test at screening and are required to use approved methods of birth control
- Use of an investigational drug within 30 days of screening
- Use of other smoking cessation aids (bupropion, nicotine replacement products)
- Use of other tobacco products
- History of allergic reactions to varenicline
- Lack capacity to provide informed consent
Where it is running
1 location listed across 1 US state.
- Corporal Michael J Crescenz VA Medical Center - Philadelphia, Pennsylvania, United States